Hangzhou Tigermed Consulting Co., Ltd.

HNGZY · OTC
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Revenue$248,054$1,686,301$1,564,144$1,535,505
% Growth-85.3%7.8%1.9%
Cost of Goods Sold$179,923$1,178,083$1,094,383$1,263,774
Gross Profit$68,130$508,218$469,761$271,731
% Margin27.5%30.1%30%17.7%
R&D Expenses$8,975$67,929$59,076$66,287
G&A Expenses$0-$67,082$180,487-$257,923
SG&A Expenses$34,229-$91,395$229,183-$354,108
Sales & Mktg Exp.$0-$24,313$48,696-$96,185
Other Operating Expenses$1,450$231,930$36,998$980,130
Operating Expenses$44,653$208,464$325,257$692,308
Operating Income$23,477$299,753$144,504-$420,577
% Margin9.5%17.8%9.2%-27.4%
Other Income/Exp. Net$85,513-$689-$879-$2,027
Pre-Tax Income$108,991$299,064$143,625-$422,603
Tax Expense$7,159$46,217$33,644$32,701
Net Income$89,012$217,868$165,469-$408,285
% Margin35.9%12.9%10.6%-26.6%
EPS0.10.250.19-0.47
% Growth-60%31.6%140.4%
EPS Diluted0.10.250.19-0.47
Weighted Avg Shares Out861,026870,888870,888862,007
Weighted Avg Shares Out Dil861,026870,888870,888862,007
Supplemental Information
Interest Income$28,952$0$0$0
Interest Expense$1,799$16,725$31,748$24,717
Depreciation & Amortization$0$0$0$0
EBITDA$110,790$309,709$187,382-$288,345
% Margin44.7%18.4%12%-18.8%